Targeted Endoradiotherapy with Lu<sub>2</sub>O<sub>3</sub>-iPSMA/-iFAP Nanoparticles Activated by Neutron Irradiation: Preclinical Evaluation and First Patient Image.

Pharmaceutics · 2022 · PMC9026501 · PMID 35456554

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In the case of 177 Lu 2 O 3 -iPSMA application for the treatment of liver metastases, the custom dose calculation is even more critical, since the distribution of the radionanosystem can exhibit highly significant variations, depending on the patient’s liver damage.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.